Alex H. Gifford

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry

Todd A. MacKenzie, Alex H. Gifford, Kathryn A. Sabadosa et al. · Annals of Internal Medicine · 2014 · 349 citations · Full text

Medicine, Biostatistics, Pediatrics +14

Prevalence of Streptococci and Increased Polymicrobial Diversity Associated with Cystic Fibrosis Patient Stability

Laura Filkins, Thomas H. Hampton, Alex H. Gifford et al. · Journal of Bacteriology · 2012 · 195 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation

Katherine E. Price, Thomas H. Hampton, Alex H. Gifford et al. · Microbiome · 2013 · 142 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8